Month: January 2024

Prosafe SE: Resignation of Board member

Written by Customer Service on January 8, 2024. Posted in Public Companies.

Simen Flaaten has notified the Chair of Prosafe’s Board of Directors that due to other commitments, he wants to resign as Director as soon as practicable possible. Mr Flaaten has been a member of the Board of Directors since 30 June 2023. Mr Flaaten’s resignation has been accepted and he will remain on the Board until a Director to replace him has been elected. Prosafe will call for an extraordinary general meeting to elect a new Director shortly. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 8 January 2024 Prosafe SE For further information, please contact: Glen O. Rødland, Chair Phone: +47 907 41 662 This information is subject to the disclosure requirements pursuant...

Global Logistics Automation Market to Surpass 160.55 Billion by 2030 Driven byRising Adoption of Machinery, Control Systems, and Software

Written by Customer Service on January 8, 2024. Posted in Mergers And Acquisitions.

SkyQuest projects that the global logistics automationmarket will attain a value of USD160.55 billion by 2030, with a CAGR of 13.2% during the forecast period (2023-2030). The global logistics automation market is witnessing rapid growth, driven by adopting machinery, control systems, and software to optimize operational efficiency in warehouses and distribution centers. Westford,USA, Jan. 08, 2024 (GLOBE NEWSWIRE) — According to SkyQuest, the ascent of robotics is profoundly reshaping the manufacturing landscape, with a notable transformation anticipated in the global logistics automation market. Projections indicate that by 2025, a substantial 45% of all manufacturing tasks will be executed by robotic technology. This seismic shift is already underway, with prominent industry giants such as Raymond Limited and Foxconn Technology...

Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024

Written by Customer Service on January 8, 2024. Posted in Public Companies.

Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024Halle (Saale) / Munich, Germany, January 8, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that members of its management team including CEO Frank Weber, MD, CBO Michael Schaeffer, PhD, and CS & IRO Anne Doering, CFA, will host investor meetings, January 8 – 10, 2024, in San Francisco, CA.Vivoryon’s management team will discuss its lead program varoglutamstat, a differentiated investigational small-molecule medicine in development to treat Alzheimer’s disease (AD). The Company remains on track to share VIVIAD Phase 2b final topline data, comprising...

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Written by Customer Service on January 8, 2024. Posted in Earnings Releases And Operating Results.

Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end Leiden, The Netherlands, January 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today updated full year 2023 guidance, including RUCONEST® and Joenja® revenues, and a progress update on the U.S. launch of Joenja® (leniolisib) for APDS. For the full year 2023, total revenues are expected to increase by 19% to approximately US$245 million (preliminary and unaudited*). Sijmen de Vries, Chief Executive Officer, commented: “We are pleased to have concluded an excellent year in which we transformed Pharming into a multi-product, commercial rare disease biopharmaceutical company. We expect 10% growth in RUCONEST®...

Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

Written by Customer Service on January 8, 2024. Posted in Public Companies.

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia Ad hoc announcement pursuant to Art. 53ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) shows superior MMR rates at week 48 vs. standard-of-care TKIs (imatinib, nilotinib, dasatinib, and bosutinib) in newly diagnosed Ph+CML-CP patients1Scemblix demonstrated a favorable safety and tolerability profile with fewer adverse events (AEs) and treatment discontinuations vs. standard-of-care TKIs; no new safety signals were observed1With current standard-of-care TKIs, more than 60% of newly diagnosed patients with CML fail to meet molecular response goals...

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Written by Customer Service on January 8, 2024. Posted in Public Companies.

ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in Geographic Atrophy (GA) to Initiate Mid-2024; First Pivotal Trial Using Vision Preservation as Primary Outcome Measure in GA Clinical Proof-of-Concept Study of ANX1502 First-in-Kind Oral Small Molecule Inhibitor of the Classical Pathway to Initiate in First Half of 2024 Recent Successful $125 Million Financing Extends Operating Runway into Second Quarter 2026 BRISBANE, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today outlined its strategic priorities...

Ascendis Pharma Introduces Vision 2030

Written by Customer Service on January 7, 2024. Posted in Public Companies.

Strategic roadmap to achieve blockbuster status for multiple products and expand the Company’s engine for future innovationCOPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference. “With unwavering focus on our values of Patients, Science, and Passion, we remain on track to fulfill Vision 3×3, with the approval already of two Endocrinology Rare Disease products and value leadership in the U.S. growth hormone market for SKYTROFA,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “Today we are introducing Vision 2030, our...

Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue

Written by Customer Service on January 7, 2024. Posted in Public Companies.

SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023. The Company shipped eight G4 instruments in the fourth quarter of 2023. Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be approximately $1.0 million, representing growth of approximately 31% compared to $765 thousand during the fourth quarter of 2022. “We are proud of the momentum we built throughout 2023, increasing our installed base of instruments and recently launching two high-impact consumable kits: the F3 flow cells and Max Read flow cells,” said Drew Spaventa, Chairman and Chief...

Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook

Written by Customer Service on January 7, 2024. Posted in Public Companies.

2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold® Following a Year of Increased Demand Expecting 2024 Galafold Revenue Growth of 11-16% at CER Successful Launches of Pombiliti™ + Opfolda™ Underway in the U.S., U.K., and Germany PRINCETON, N.J., Jan. 07, 2024 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its preliminary and unaudited 2023 revenue, corporate updates, and full-year 2024 outlook. In 2023, Amicus met or exceeded its strategic priorities, highlighted by:Sustaining double-digit Galafold revenue growth Securing FDA, EMA, and MHRA approvals for Pombiliti + Opfolda Initiating successful global...

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Written by Customer Service on January 7, 2024. Posted in Public Companies.

Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024 Progress of Radio-DARPin Therapy (RDT) platform: Improved tumor to kidney uptake ratio enables expansion of RDT pipeline; first data on DLL3 as lead candidate; to be co-developed as 212Pb-based RDT in new partnership with Orano Med Introduction of first program from the Switch-DARPin platform: the cKIT x CD16a x CD47 Switch-DARPin allows local conditional immune cell activation for targeted killing of hematopoietic stem cells (HSC) as next-generation conditioning for hematopoietic stem cell transplantation (HSCT) in AML and beyond.ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN;...

Month: January 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals